6JH0.F IN8bio, Inc.

Healthcare Biotechnology Frankfurt Exchange
0.8250 EUR
Close of Nov 11, 2026
0.7250 2.12
Market cap
EUR 8.92M
P/E
-
P/B
0.54x
ROE
-107.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6JH0.F undervalued?

Graham number

The Graham number of IN8bio, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IN8bio, Inc. fundamental analysis

No fundamental analysis for IN8bio, Inc. yet.

IN8bio, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IN8bio, Inc.

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; a…

Full company profile